Business · 09/10/2009
FDA Classifies Respiratory Viral Panel Multiplex Nucleic Acid Assay as Class II Device
The FDA has classified the respiratory viral panel multiplex nucleic acid assay as a Class II device, requiring special controls to ensure the device's safety and effectiveness, and has made the relevant guidance documents available.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →